Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825484 | 0.83 | PTGS1 (0.58) | PTGS1PTGS2AOC3HTTTSHR | |
| SCHEMBL17541509 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTALOX5 | |
| SCHEMBL19287601 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTALOX5 | |
| SCHEMBL14376154 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2AOC3HTTALOX5 | |
| SCHEMBL2453938 | 0.79 | PTGS1 (0.50) | PTGS1PTGS2AOC3HTTTSHR | |
| SCHEMBL22785949 | 0.77 | AOC3 (0.64) | PTGS1PTGS2AOC3HTTTSHR | |
| SCHEMBL22785898 | 0.77 | AOC3 (0.64) | PTGS1PTGS2AOC3HTTTSHR | |
| SCHEMBL12181345 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2AOC3HTTTSHR | |
| SCHEMBL14777215 | 0.76 | PTGS1 (0.58) | PTGS1PTGS2AOC3HTTMAPT | |
| SCHEMBL14787788 | 0.76 | PTGS1 (0.58) | PTGS1PTGS2AOC3HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765728-B2 | [1,5]-diazocin derivatives | MELLITECH (FR) | 2014-07-01 | — | — | US | disclosed |
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | MELLITECH (FR) | 2012-09-06 | — | — | US | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | IAPP, INSR, GLP1R | PTGS1 670/4885PTGS2 2022/4885AOC3 3951/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | PTGS1 1445/4885PTGS2 899/4885AOC3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.